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I N T R O D U C T I O N
This document is the ¢rst full description of the method of
determining clinical breakpoints for antibiotics (for de¢ni-
tions of terminology, see Clinical Microbiology and Infection,
1998; 4: 291^6) that has been used for the past 10 years by the
European Study Group on Breakpoints (ESGAB) and now to
be used by EUCAST, its successor. Because of the diversity of
methodology of susceptibility testing in Europe, particularly
in diskmethods, we have determined breakpoints only in rela-
tion to MICs. Informal assessment has shown that MICs for
common non-fastidious bacteria, competently determined by
the methods described by a number of national societies, are
very close and often identical.We are in the process of formal
studyof this comparability.
In order to determine breakpoints, the EUCAST Break-
points Subcommittee requires information from those pro-
moting the antimicrobial agent. In the pursuit of international
collaboration, we have, whenever possible, used the wording
of aversion of theNCCLS documentM23 whichwas the sub-
ject of discussion at the time the EUCASTdocument was pro-
duced. The wording of this EUCASTdocument di¡ers from
that of the published versions of M23 and cannot be used as a
substitute when it is intended to follow NCCLS guidelines.
Rather, its purpose is to facilitate the provision of documenta-
tion required of those seeking a breakpoint determination in
Europe.
Information required for the determination of antimicrobial
susceptibility test breakpoints
In vitro drug characteristics
Information is required on the use of diluents and solvents;
preparation of stock solutions; stability of the drug in appro-
priate concentrations at storage and incubation temperature;
and the relationship or comparability of MIC endpoints
de¢ned by di¡erent methods, for broth and agar methods and
media, for relevant representative organisms.
Distribution of susceptibility of organisms
MICs must be determined on at least 500 isolates (and at least
300 anaerobes in addition if relevant, each species in su¤cient
numbers to establish norms, with a note on relative prevalence
among clinical isolates), which must include examples of
clinically relevant species appropriate to the class of com-
pound and its proposed clinical use.Theymust include isolates
showing important resistance mechanisms. For example,
methicillin-resistant Stapylococcus aureus (MRSA) and coagu-
lase-negative staphylococci should be included for the evalua-
tion of antistaphylococcal agents.
The MIC distributions must be shown (not MIC50,
MIC90, etc.), and compared with those obtained for recent
clinical isolates obtained from large geographically diverse
surveys.
Pharmacokinetics and pharmacodynamics
Methods for measurement of drug concentrations in serum
and body £uids must be provided. If bioassay and other meth-
ods are available, their relative performancemust be shown.
Actual plots must be provided of serum or plasma levels in
humans over time following expected dosages and methods of
administration. Concentrations in cerebrospinal £uid must be
presented if the drug is to be used for the treatment of menin-
gitis. If available, data from target patient populations should
be presented. The number of subjects or patients, characteris-
tics, and intra-and inter-individual variability of measurments
must be included.
Pharmacokinetic parameters that are also useful for simula-
tion, calculation of pharmacokinetic/pharmacodynamic rela-
tionships, and comparisons with other drugs of the same class
must be provided.These parameters must include bioavailabil-
ity, Cmax, AUC, volume of distribution, protein binding (and
its e¡ect onMIC and pharmacokinetic and pharmacodynamic
parameters), metabolism (including data on microbiological
activity of metabolites), excretion (with kinetics and e¡ects of
pH and cations in urine, if relevant), clearance, and elimina-
tion half-life. The number of subjects should be governed by
good statistical assessments.
Data on di¡erences in AUC, expected peak and trough
serum concentrations, and pharmacokinetic/pharmacody-
namic parameters (e.g. AUC: proposed MIC breakpoint ratio)
with anticipated dosage regimens are helpful, if available. As
well as data on normal human subjects, data on target popula-
tions which might include children, the elderly and popula-
tions with special dosage requirements (e.g. in renal or hepatic
failure) are desirable.
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An analysis of the relationship between pharmacokinetic
and pharmacodynamic parameters and e¤cacy must be
included. Serum concentrations resulting from proposed
dosage regimens in humans should be used. The analysis
might include (but not be limited to): the time for which
serum or plasma levels exceed the MIC of relevant (including
anaerobic and fastidious) organisms; peak serum or plasma
level/MIC ratio; and area under the drug serum concentration
(AUC)/MIC ratio. Similar calculations for related drugs of the
same class should be provided. Data for this analysis might be
derived from experimental models of infection, from humans
given proposed dosage schedules, or from clinical studies.
Data on the postantibiotic e¡ect and on the impact of increas-
ing drug concentrations on bacterial killingmay be helpful.
When basic information has been collected on the in vitro
activity of the drug, distribution of MICs and pharmacoki-
netics/pharmacodynamics, it will be desirable to establish ten-
tative breakpoints.
Correlation of test results with clinical outcome
During the clinical evaluation of antimicrobial agents, clinical
cure and bacterial eradication rates must be correlated with
appropriate in vitro tests results to con¢rm the validity of the
proposed interpretive criteria.There may be occasions when a
clear breakpoint can be determined from the clinical data. In
other situations, the clinical data will serve more to support
other types of data (microbiological and pharmacokinetic/
pharmacodynamic) in determining interpretive criteria.
In the course of development of an antimicrobial agent,
the manufacturer will conduct clinical studies that will yield a
large volume of data. Optimally, the design and evaluation of
studies should conform to the most recent guidelines of ESC-
MID and IDSA. The manufacturer must provide, in a sum-
marized fashion, all relevant data needed to make breakpoint
determinations. The manufacturer should note if the data are
di¡erent from those submitted to regulatory authorities, and
give reasons for the di¡erences.
The following points should be considered:
A clear description of the clinical protocols must be given,
including:
description of the population studied;
speci¢c inclusion/exclusion criteria;
dosage and duration of study and comparative drug
therapy;
times of initial, on-therapy and follow-up microbiological
and clinical assessments, visits and test of cure
evaluability criteria;
de¢nitions of c`linical'and `bacteriological' response.
When the category `improved' is used as a clinical outcome,
this must be clearly de¢ned:
If adjunctive therapy is permitted, this must be so stated.
If patients are permitted to switch from the study antimicro-
bial regimen to another (e.g. parenteral to oral switch), this
must be so stated, and criteria for such a change clearly
de¢ned.
If surgical procedures are part of the routine care of an infec-
tion type, details of such procedures within the study must be
discussed.
All clinical data relevant to breakpoint analysis, including
an analysis of evaluable cases and an intent-to-treat analysis of
microbiologically documented cases, must be presented. In
addition, summary results for the comparative arms must be
presented by individual study. To allow optimal evaluation,
clinical data must be presented separately for sites and types of
infection (e.g. urinary tract infection, complicated or uncom-
plicated; pneumonia, community acquired or nosocomial). In
addition, subsets of patients with bacteremia must be pre-
sented.The data analysis must be based on responses at the `test
of cure'and at the subsequent long-term follow-up visits. All
failures must be carried forward to subsequent evaluations.
The data presented must be relevant to the anticipated use
of the agent in clinical practice, and the organisms must be
relevant to the clinical site of infection studied.
All clinical and/or microbiological failures must be pre-
sented separately according to the infecting bacterium, MIC
and site of infection.
In vitro data must be presented as MICs, not simply as s`us-
ceptible' or r`esistant', for individual bacterial species relevant
to the anticipated use of the drug. Quality control datamust be
generated and recorded for all clinical isolate susceptibility
determinations.
Infections due to single or predominant pathogens must be
presented separately from true polymicrobial infections.
Data must be presented for both clinical (cure, improved,
failure) and bacterial responses.When the category `improved'
is used, clinical response data must be broken down into sepa-
rate c`ure', `` improved'' and `failure' categories. Bacteriologic
response data must be presented with and without `presumed'
outcomes included. In addition, data must be presented for
eachMIC.
Information about species or isolates that are resistant or
have MICs near the proposed breakpoint is of particular inter-
est and should be presented, for both evaluable and intent-to-
treat populations.
When an antimicrobial is developed that is a combination
product, then a justi¢cation for the selected ratios or concen-
trations must be presented.
Quality control
During the drug development process, testing of recognized
quality control strains must be performed to establish preli-
minary and subsequently de¢nitive quality control limits and
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to determine the impact of procedural variations on test per-
formance. Testing must be performed with all appropriate
methods to establish equivalency of methods (e.g. agar, dilu-
tion and brothmicrodilution). Such testingmay be carried out
in one laboratory.
Resolving differences
Numerous bodies independently establish interpretive criteria
and quality control limits based on evaluation of extensive
data.These independent processes can produce interpretations
that are discrepant. Every e¡ort must be made to resolve such
discrepancies.
R E V IS I O N S
This document was approved by EUCAST in August 2000.
Revisions will be considered by the Breakpoints Sub-com-
mittee of EUCASTduring 2001. Proposals for changes should
be sent to EUCASTvia EUCAST Secretariat, Cornelia Has-
selman, Martin-Buber-Weg 17, D-81245 Munich, Germany
(Tel: 49 89 89712003, Fax: 49 89 8971 2004; E-mail: Cor-
nelia.Hasselman@t-online.de).
Since parts of this document are similar to selected sections of NCCLS document M23, and in recognition of the years of e¡ort on the part of
NCCLSand its Subcommittee onAntimicrobial SusceptibilityTesting, we sought the agreement ofNCCLSon utilization of this text.NCCLShas
granted permission for such adaptation of itsM23 (Development of InVitro SusceptibilityTestingCriteria andQualityControl Parameters) guideline.
Copies of the currentM23 editionmaybe obtained fromNCCLS, 940WestValleyRoad, Suite1400,Wayne, PA19087,USA.
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